Company Filing History:
Years Active: 2021
Title: Changchun Deng: Innovator in Cancer Treatment
Introduction
Changchun Deng is a notable inventor based in Jericho, NY (US). He has made significant contributions to the field of cancer treatment through his innovative research and development of new compounds. His work primarily focuses on addressing the challenges posed by c-Myc overexpression in various cancers.
Latest Patents
Changchun Deng holds a patent for "Compounds for reducing c-Myc in c-Myc overexpressing cancers." This invention relates to new compounds that effectively reduce c-Myc expression, which is particularly useful in treating hematological cancers such as aggressive B- and T-cell lymphomas. The compounds can be combined with adjunct c-Myc inhibitor agents, including PI3K inhibitors, CK-1 inhibitors, Akt-inhibitors, proteasome inhibitors, and mTor inhibitors. The c-Myc reducing agent may serve as a lead-in treatment to initiate the reduction of c-Myc prior to the administration of adjunct cancer therapeutic agents. This innovative approach modulates the disease state of c-Myc overexpressing cancers, making them less malignant and more susceptible to additional cancer therapies. Changchun Deng has 1 patent to his name.
Career Highlights
Changchun Deng is affiliated with Columbia University, where he conducts his research and development work. His contributions to the field of oncology have been recognized for their potential impact on cancer treatment strategies.
Collaborations
Some of his notable coworkers include Mark Lipstein and Owen Anthony O'Connor. Their collaborative efforts contribute to advancing research in cancer therapies.
Conclusion
Changchun Deng's innovative work in developing compounds to reduce c-Myc expression represents a significant advancement in cancer treatment. His research holds promise for improving therapeutic outcomes for patients with c-Myc overexpressing cancers.